TISIDB

Summary
Symbol	LAMTOR1
Name	late endosomal/lysosomal adaptor, MAPK and MTOR activator 1
Aliases	FLJ20625; p27RF-Rho; Pdro; Ragulator1; p27kip1 releasing factor from RhoA; protein associated with DRMs and ......
Chromosomal Location	11q13.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Late endosome membrane; Lipid-anchor; Cytoplasmic side. Lysosome membrane; Lipid-anchor; Cytoplasmic side. Cell membrane.
Domain	PF15454 Late endosomal/lysosomal adaptor and MAPK and MTOR activator
Function	As part of the Ragulator complex it is involved in amino acid sensing and activation of mTORC1, a signaling complex promoting cell growth in response to growth factors, energy levels, and amino acids. Activated by amino acids through a mechanism involving the lysosomal V-ATPase, the Ragulator functions as a guanine nucleotide exchange factor activating the small GTPases Rag. Activated Ragulator and Rag GTPases function as a scaffold recruiting mTORC1 to lysosomes where it is in turn activated. LAMTOR1 is directly responsible for anchoring the Ragulator complex to membranes. Also required for late endosomes/lysosomes biogenesis it may regulate both the recycling of receptors through endosomes and the MAPK signaling pathway through recruitment of some of its components to late endosomes. May be involved in cholesterol homeostasis regulating LDL uptake and cholesterol release from late endosomes/lysosomes. May also play a role in RHOA activation.

> Gene Ontology [ TOP ]
Biological Process	GO:0001101 response to acid chemical GO:0001881 receptor recycling GO:0001919 regulation of receptor recycling GO:0006869 lipid transport GO:0006914 autophagy GO:0007032 endosome organization GO:0007033 vacuole organization GO:0007040 lysosome organization GO:0007050 cell cycle arrest GO:0008202 steroid metabolic process GO:0010872 regulation of cholesterol esterification GO:0010874 regulation of cholesterol efflux GO:0010876 lipid localization GO:0015850 organic hydroxy compound transport GO:0015918 sterol transport GO:0016049 cell growth GO:0016236 macroautophagy GO:0019216 regulation of lipid metabolic process GO:0019218 regulation of steroid metabolic process GO:0030258 lipid modification GO:0030301 cholesterol transport GO:0031929 TOR signaling GO:0032006 regulation of TOR signaling GO:0032008 positive regulation of TOR signaling GO:0032368 regulation of lipid transport GO:0032371 regulation of sterol transport GO:0032374 regulation of cholesterol transport GO:0032418 lysosome localization GO:0032439 endosome localization GO:0033344 cholesterol efflux GO:0034433 steroid esterification GO:0034434 sterol esterification GO:0034435 cholesterol esterification GO:0035376 sterol import GO:0042632 cholesterol homeostasis GO:0043112 receptor metabolic process GO:0043200 response to amino acid GO:0043410 positive regulation of MAPK cascade GO:0045786 negative regulation of cell cycle GO:0051640 organelle localization GO:0055088 lipid homeostasis GO:0055092 sterol homeostasis GO:0060620 regulation of cholesterol import GO:0070508 cholesterol import GO:0071229 cellular response to acid chemical GO:0071230 cellular response to amino acid stimulus GO:0071417 cellular response to organonitrogen compound GO:0080171 lytic vacuole organization GO:2000909 regulation of sterol import
Molecular Function	GO:0005085 guanyl-nucleotide exchange factor activity GO:0032947 protein complex scaffold
Cellular Component	GO:0005765 lysosomal membrane GO:0005770 late endosome GO:0010008 endosome membrane GO:0031902 late endosome membrane GO:0044440 endosomal part GO:0045121 membrane raft GO:0071986 Ragulator complex GO:0098589 membrane region GO:0098852 lytic vacuole membrane GO:0098857 membrane microdomain

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04150 mTOR signaling pathway
Reactome	R-HSA-2262752: Cellular responses to stress R-HSA-380972: Energy dependent regulation of mTOR by LKB1-AMPK R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-1632852: Macroautophagy R-HSA-6798695: Neutrophil degranulation R-HSA-109704: PI3K Cascade R-HSA-109703: PKB-mediated events R-HSA-162582: Signal Transduction R-HSA-74752: Signaling by Insulin receptor R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-5628897: TP53 Regulates Metabolic Genes R-HSA-3700989: Transcriptional Regulation by TP53 R-HSA-165159: mTOR signalling R-HSA-166208: mTORC1-mediated signalling

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04150 mTOR signaling pathway

Reactome

R-HSA-2262752: Cellular responses to stress
R-HSA-380972: Energy dependent regulation of mTOR by LKB1-AMPK
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-1632852: Macroautophagy
R-HSA-6798695: Neutrophil degranulation
R-HSA-109704: PI3K Cascade
R-HSA-109703: PKB-mediated events
R-HSA-162582: Signal Transduction
R-HSA-74752: Signaling by Insulin receptor
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-5628897: TP53 Regulates Metabolic Genes
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-165159: mTOR signalling
R-HSA-166208: mTORC1-mediated signalling

Summary
Symbol	LAMTOR1
Name	late endosomal/lysosomal adaptor, MAPK and MTOR activator 1
Aliases	FLJ20625; p27RF-Rho; Pdro; Ragulator1; p27kip1 releasing factor from RhoA; protein associated with DRMs and ......
Chromosomal Location	11q13.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between LAMTOR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	LAMTOR1
Name	late endosomal/lysosomal adaptor, MAPK and MTOR activator 1
Aliases	FLJ20625; p27RF-Rho; Pdro; Ragulator1; p27kip1 releasing factor from RhoA; protein associated with DRMs and ......
Chromosomal Location	11q13.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of LAMTOR1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.18; FDR: 0.04630	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	LAMTOR1
Name	late endosomal/lysosomal adaptor, MAPK and MTOR activator 1
Aliases	FLJ20625; p27RF-Rho; Pdro; Ragulator1; p27kip1 releasing factor from RhoA; protein associated with DRMs and ......
Chromosomal Location	11q13.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of LAMTOR1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.231	0.309
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.28	0.924
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.193	0.93
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.03	0.919
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.135	0.943
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.241	0.922
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.293	0.462
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.128	0.94
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.524	0.787
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.023	0.992
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.242	0.943
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.127	0.022

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of LAMTOR1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	LAMTOR1
Name	late endosomal/lysosomal adaptor, MAPK and MTOR activator 1
Aliases	FLJ20625; p27RF-Rho; Pdro; Ragulator1; p27kip1 releasing factor from RhoA; protein associated with DRMs and ......
Chromosomal Location	11q13.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LAMTOR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	LAMTOR1
Name	late endosomal/lysosomal adaptor, MAPK and MTOR activator 1
Aliases	FLJ20625; p27RF-Rho; Pdro; Ragulator1; p27kip1 releasing factor from RhoA; protein associated with DRMs and ......
Chromosomal Location	11q13.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LAMTOR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LAMTOR1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	LAMTOR1
Name	late endosomal/lysosomal adaptor, MAPK and MTOR activator 1
Aliases	FLJ20625; p27RF-Rho; Pdro; Ragulator1; p27kip1 releasing factor from RhoA; protein associated with DRMs and ......
Chromosomal Location	11q13.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LAMTOR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	LAMTOR1
Name	late endosomal/lysosomal adaptor, MAPK and MTOR activator 1
Aliases	FLJ20625; p27RF-Rho; Pdro; Ragulator1; p27kip1 releasing factor from RhoA; protein associated with DRMs and ......
Chromosomal Location	11q13.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of LAMTOR1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	LAMTOR1
Name	late endosomal/lysosomal adaptor, MAPK and MTOR activator 1
Aliases	FLJ20625; p27RF-Rho; Pdro; Ragulator1; p27kip1 releasing factor from RhoA; protein associated with DRMs and ......
Chromosomal Location	11q13.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between LAMTOR1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	LAMTOR1
Name	late endosomal/lysosomal adaptor, MAPK and MTOR activator 1
Aliases	FLJ20625; p27RF-Rho; Pdro; Ragulator1; p27kip1 releasing factor from RhoA; protein associated with DRMs and ......
Chromosomal Location	11q13.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting LAMTOR1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse LAMTOR1